Similarly, SHR6390 (dalpiciclib), a structurally optimised analogue of palbociclib and ribociclib, has demonstrated therapeutic potential in both ER+/HER2− breast cancer and head and neck mucosal melanoma, with improved binding properties and tolerability [28,29]. Here, ESR1 is linked to breast carcinoma.